Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HNRNPU Lactylation and the PHGDH Axis
2026-11-22
A cervical-cancer study connects lactate-responsive HNRNPU K181 lactylation with PHGDH transcript regulation, serine metabolism and tumor growth. Its genetic and molecular evidence is stronger than its pharmacological attribution, because the reported drug perturbation involved a multi-kinase inhibitor rather than a selective lactylation agent.
5-EdU and Glial Repair After Spinal Cord Injury
2026-11-21
5-Ethynyl-2′-deoxyuridine (5-EdU) detects newly synthesized DNA, but an EdU signal is not equivalent to cell division, tissue repair, or functional recovery. In a mouse spinal cord injury study, the assay belongs to the measurement layer of a broader causal model in which astrocytic CSF1 and microglial IFN-β reciprocally support lesion organization and neurological recovery.
HNRNPU Lactylation and the Limits of (R)-MG132
2026-11-20
A cervical-cancer study links lactate-responsive HNRNPU K181 lactylation to PHGDH RNA regulation, serine metabolism, and tumor growth. Its pharmacological evidence centers on pazopanib, whereas (R)-MG132 belongs to a separate proteasome-control framework and should not be treated as evidence for this metabolic mechanism.
What (R)-MG132 Can Show in Cancer Studies
2026-11-20
The cervical-cancer study supports a lactylation–HNRNPU–PHGDH axis, but its pharmacological evidence remains pleiotropic. (R)-MG132 is best understood as a stereochemical proteasome control, not as evidence for that metabolic mechanism.
NCOR2 and Lipid Stress in ENKTL
2026-11-19
A study in EBV-positive extranodal NK/T-cell lymphoma models links celastrol response to NCOR2–HDAC3 perturbation, altered chromatin regulation, lipid-associated stress and apoptosis. The findings support a multi-layered mechanism, while leaving direct target engagement, selectivity and clinical relevance unresolved.
Subtractive Engineering of Stem Cell Tissues
2026-11-19
A 2026 study introduced programmable apoptosis circuits that remove selected cell states during morphogenesis rather than relying only on endpoint purification. Its results support a conceptual framework for improving organoid and embryoid organization, while leaving important questions about specificity, causality, and transferability.
(R)-MG132 and the HNRNPU–PHGDH Evidence
2026-11-18
The cervical-cancer study supports a lactate–HNRNPU K181–PHGDH axis that connects post-translational regulation with serine metabolism and tumor-cell growth. (R)-MG132 has a different interpretive role: as a low-activity MG-132 enantiomeric control for ubiquitin-proteasome system research, it should not be treated as the causal perturbation or validation of the reported lactylation mechanism.
HNRNPU Lactylation and Proteasome-Control Limits
2026-11-18
Evidence from cervical-cancer models links HNRNPU K181 lactylation with PHGDH transcript regulation, serine metabolism and tumor growth. (R)-MG132, the MG-132 enantiomer, belongs to a different evidentiary layer: it is described as a low-activity proteasome-control compound, useful for separating proteasome-dependent effects from pathway-specific claims but not for establishing the HNRNPU mechanism itself.
When Context Changes a Proteasome Result
2026-11-17
A cervical-cancer study connects HNRNPU K181 lactylation with PHGDH regulation and serine metabolism, while (R)-MG132 belongs to a separate proteasome-control context. Reading these results correctly requires distinguishing pathway evidence from comparator logic, downstream readouts, and pharmacological specificity.
When Context Changes a Molecular Result
2026-11-17
The meaning of a molecular result depends on the model, perturbation, comparator, and readout. The cervical-cancer study of HNRNPU K181 lactylation illustrates how protein-level associations, genetic perturbations, and broad pharmacology support different levels of mechanistic inference, while (R)-MG132 belongs to a distinct proteasome-control context rather than serving as direct evidence for this metabolic pathway.
HNRNPU Lactylation Rewires Serine Metabolism
2026-11-16
A 2026 cervical-cancer study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine biosynthesis and tumor growth. The findings support a mechanistic lactate–RNA metabolism axis, while the study’s pharmacological evidence came from pazopanib rather than (R)-MG132. The latter is better interpreted as a low-activity proteasome-control compound, not as evidence for the reported metabolic pathway.
HNRNPU Lactylation Rewires Cervical Cancer Metabolism
2026-11-16
A 2026 study presents HNRNPU lysine 181 lactylation as a metabolic-to-post-transcriptional link that stabilizes PHGDH transcripts, supports serine biosynthesis, and promotes cervical cancer growth. Its genetic evidence is mechanistically informative, while pharmacological interpretation remains limited by the pleiotropic activity of pazopanib and by the study’s model systems.
(R)-MG132 and HNRNPU Lactylation
2026-11-15
A literature-focused analysis of how HNRNPU K181 lactylation was linked to PHGDH regulation, serine metabolism, and cervical-cancer growth—and why (R)-MG132 belongs to proteasome-control interpretation rather than direct validation of that pathway.
When Context Changes a Proteasome Result
2026-11-14
The meaning of a proteasome-associated result depends on the model, assay layer, comparator and causal question. In the cervical-cancer study discussed here, (R)-MG132 is best understood as a stereochemical control for proteasome-dependent effects, while the principal mechanistic evidence concerns HNRNPU K181 lactylation, PHGDH RNA regulation and serine metabolism.
How (R)-MG132 Sharpens Proteasome Causal Inference
2026-11-13
The MG-132 enantiomer (R)-MG132 is most informative as a low-activity proteasome-control compound, not as evidence for the HNRNPU–PHGDH pathway itself. In the cervical-cancer study, genetic perturbations supported a model in which HNRNPU K181 lactylation stabilizes PHGDH-related transcripts and promotes serine-metabolism-dependent growth, while Pazopanib supplied pharmacological evidence with important multi-target limitations.